ArticleCureus2023
The Treatment of Insomnia Secondary to Generalized Anxiety Disorder: Evaluating Escitalopram Use With Concomitant High-Resolution, Relational, Resonance-Based, Electroencephalic Mirroring (HIRREM).
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient autonomy is important. However, what if a patient seeks out poorly studied treatment options? In this case report, we describe a patient with insomnia secondary to generalized anxiety disorder (GAD) who was prescribed escitalopram but additionally used High-Resolution, Relational, Resonance-Based, Electroencephalic Mirroring (HIRREM) therapy. HIRREM is an electroencephalogram (EEG)-based therapy that has been evaluated for use in the treatment of various conditions including insomnia. However, there has only been one randomized clinical trial supporting the use of HIRREM for insomnia, and the Food and Drug Administration (FDA) has not approved HIRREM for insomnia. A few months after the patient initiated HIRREM therapy and escitalopram cessation, the patient's insomnia did not recur. We propose a case for how we approached educating a patient who was seeking out an alternative poorly tested therapy by helping him perform a cost-benefit analysis composed of treatment efficacy, cost, and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.